The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

The FDA has accepted for Priority Review the New Drug Application for centanafadine for the treatment of ADHD in multiple populations.

ADHD is associated with impulsivity, hyperactivity, and trouble with focus, but kids with ADHD may also struggle with motor ...

ADHD can interfere with your quality of life and disrupt your work schedule. We know how busy life can get, and sometimes, it may feel impossible to make the time to see an in-person care provider.

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Women are driving soaring use of ADHD medication, experts say. Researchers from the University of Oxford highlighted a 20-fold rise in use of drugs to manage the condition among w ...

ADHD medication presciptions have surged in the UK over the past decade. Women have driven the record numbers, research ...

Prescriptions of ADHD medicines has tripled in the UK over the past decade with a particular stark increase in women aged ...